63 results
8-K
EX-1.1
SYRE
Spyre Therapeutics Inc.
28 Apr 20
Entry into a Material Definitive Agreement
4:28pm
A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated April 27, 2020 and each “free-writing prospectus” (as defined pursuant to Rule 405 under … Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate
8-K
EX-1.1
SYRE
Spyre Therapeutics Inc.
6 Feb 19
Entry into a Material Definitive Agreement
9:40pm
A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated February 5, 2019 and each “free-writing prospectus” (as defined pursuant to Rule 405 … Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate
8-K
EX-99.2
SYRE
Spyre Therapeutics Inc.
15 Nov 23
Other Events
5:14pm
Endpoints) Phase 3 trial (“PEACE Trial”) and related Biologics License Application (“BLA”) package to file with the United States Food and Drug … , the Company modified the agreement with Immedica to provide certain additional services in relation to the PEACE Phase 3 Trial and BLA package performance
8-K
EX-99.1
iugsmg5cnirvonqxnk4
15 Nov 23
Other Events
5:14pm
8-K
29to6k4b 1ivec1
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.1
kx080jl4ajmesjfyrrry
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.1
40n5oe
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
EX-99.1
2b9e9qi8pwbl78ak2j
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
8-K
EX-99.1
nkkhqvzj
5 Jan 22
Regulation FD Disclosure
7:01am